PRME — Prime Medicine, Share Price
0.000.00%
Last trade - 00:00- $536.43m
- $400.94m
- $4.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.99 | ||
| Price to Tang. Book | 6.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 132.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -79.95% | ||
| Return on Equity | -216.07% | ||
| Operating Margin | -5121.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 2.98 | 4.63 | 4.25 | 6.06 | -2.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its gene editing technology enables targeted modifications to genomic deoxyribonucleic acid (DNA) without introducing double-stranded breaks. The Company pipeline includes wholly owned in vivo programs targeting liver genetic diseases Wilson Disease, Alpha-1 Antitrypsin Deficiency (AATD) as well as early-stage discovery efforts in Cystic Fibrosis (CF). The PM359 is an ex vivo prime editing program designed to correct the GT mutation in the NCF1 gene, the most common cause of Chronic Granulomatous Disease (CGD). This program provides validation of prime editing in human cells. The Wilson Disease is a rare autosomal recessive disorder caused by loss-of-function mutations in ATP7B.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- September 13th, 2019
- Public Since
- October 20th, 2022
- No. of Shareholders
- 14
- No. of Employees
- 146
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 180,617,451
- Address
- 60 First St., CAMBRIDGE, 02141
- Web
- https://primemedicine.com/
- Phone
- +1 3026587581
- Contact
- Hannah Deresiewicz
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for PRME
Prime Medicine Inc Annual Shareholders Meeting
Q2 2026 Prime Medicine Inc Earnings Release
Q3 2026 Prime Medicine Inc Earnings Release
Similar to PRME
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the Prime Medicine, share price?
As of Today at 13:45 UTC, shares in Prime Medicine, are trading at $2.97. This share price information is delayed by 15 minutes.
How has the Prime Medicine, share price performed this year?
Shares in Prime Medicine, last closed at $2.97 and the price had moved by +141.46% over the past 365 days. In terms of relative price strength the Prime Medicine, share price has outperformed the S&P500 Index by +87.49% over the past year.
What are the analyst and broker recommendations for Prime Medicine,?
The overall consensus recommendation for Prime Medicine, is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Prime Medicine, dividend yield?
Prime Medicine, does not currently pay a dividend.
Does Prime Medicine, pay a dividend?
Prime Medicine, does not currently pay a dividend.
When does Prime Medicine, next pay dividends?
Prime Medicine, does not currently pay a dividend.
How do I buy Prime Medicine, shares?
To buy shares in Prime Medicine, you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Prime Medicine,?
As of the previous close price of $2.97, shares in Prime Medicine, had a market capitalisation of $536.43m.
Where are Prime Medicine, shares listed?
Here are the trading details for Prime Medicine,:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: PRME
What kind of share is Prime Medicine,?
Based on an overall assessment of its quality, value and momentum Prime Medicine, is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Prime Medicine, share price forecast for 2026?
The analyst consensus target price for shares in Prime Medicine, is $7.04. That is 137.04% above the last closing price of $2.97.
Analysts covering Prime Medicine, currently have a consensus Earnings Per Share (EPS) forecast of -$0.99 for the next financial year.
Find out moreWhat is the trend in the Prime Medicine, share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prime Medicine,. Over the past six months, its share price has underperformed the S&P500 Index by -26.59%.
As of the last closing price of $2.97, shares in Prime Medicine, were trading -25.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Prime Medicine, PE Ratio?
The Prime Medicine, PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Prime Medicine,?
We do not have data on Prime Medicine,'s directors